Investor FAQs

Show all

Our corporate offices are located at 8000 Marina Boulevard, Suite 200, Brisbane, California 94005-1884
The company was founded on June 24, 2011 as Allergen Research Corporation (ARC), a Delaware corporation. In May 2015, we changed our name to Aimmune Therapeutics, Inc.
Our CUSIP number is 00900T 107.
Aimmune is listed on the Nasdaq Global Select Market under the ticker symbol AIMT. Our initial public offering (IPO) was on August 5, 2015.
Investors may purchase Aimmune’s stock through a licensed securities broker. We do not offer a direct purchase plan for investors.
Aimmune’s transfer agent is Equiniti:
EQ Shareowner Services
1110 Centre Pointe Curve Suite 101
Mendota Heights, MN 55120
T (800) 468-9716
Please contact our transfer agent, Wells Fargo Shareowner Services.
Wells Fargo Shareowner Services
P.O. Box 64874
St. Paul, MN 55164-0874
(800) 468-9716 Toll-Free
(651) 450-4064 Outside of the United States
Aimmune does not pay cash dividends on its common stock.
Our independent auditors are KPMG LLP.
55 2nd Street Suite 1400
San Francisco, CA 94105
(415) 963-5100
Our outside legal counsel is Latham & Watkins LLP.
Latham & Watkins LLP
140 Scott Drive
Menlo Park, CA 94025
(650) 328-4600
Our fiscal year-end is December 31.
Please submit an inquiry via our contact form.